BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 28952212)

  • 1. The prognostic significance of cyclin D1 expression in patients with triple-negative breast cancer.
    Bolat Kucukzeybek B; Vedat Bayoglu I; Kucukzeybek Y; Alacacioglu A; Yigit S; Akder Sari A; Akyol M; Oktay Tarhan M
    J BUON; 2017; 22(4):947-952. PubMed ID: 28952212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
    Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
    Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation.
    Turner BC; Gumbs AA; Carter D; Glazer PM; Haffty BG
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1169-76. PubMed ID: 10889369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of ROR1 has prognostic significance in triple negative breast cancer.
    Chien HP; Ueng SH; Chen SC; Chang YS; Lin YC; Lo YF; Chang HK; Chuang WY; Huang YT; Cheung YC; Shen SC; Hsueh C
    Virchows Arch; 2016 May; 468(5):589-95. PubMed ID: 26874851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
    Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
    Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TPX2 as a Novel Prognostic Indicator and Promising Therapeutic Target in Triple-negative Breast Cancer.
    Jiang Y; Liu Y; Tan X; Yu S; Luo J
    Clin Breast Cancer; 2019 Dec; 19(6):450-455. PubMed ID: 31494045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
    Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
    PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
    Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
    World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
    Choi JE; Kang SH; Lee SJ; Bae YK
    Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
    Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
    BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
    Villegas SL; Darb-Esfahani S; von Minckwitz G; Huober J; Weber K; Marmé F; Furlanetto J; Schem C; Pfitzner BM; Lederer B; Engels K; Kümmel S; Müller V; Mehta K; Denkert C; Loibl S
    Breast Cancer Res Treat; 2018 Feb; 168(1):179-187. PubMed ID: 29177689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinicopathologic features and prognosis of triple negative breast cancer].
    Zhou T; Yang L; Ma GM; Li CX; Bai Y; Zhao JA; Wang XL; Geng CZ
    Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2261-4. PubMed ID: 20095338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival outcome of weak estrogen/progesterone receptor expression in HER2 negative breast cancer is similar to triple negative breast cancer.
    Liao GS; Dai MS; Hsu HM; Chu CH; Hong ZJ; Fu CY; Chou YC; Huang TC; Yu JC
    Eur J Surg Oncol; 2017 Oct; 43(10):1855-1861. PubMed ID: 28756019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.
    Li CY; Zhang S; Zhang XB; Wang P; Hou GF; Zhang J
    Asian Pac J Cancer Prev; 2013; 14(6):3779-84. PubMed ID: 23886182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer.
    Kim YJ; Sung M; Oh E; Vrancken MV; Song JY; Jung K; Choi YL
    Cancer Biol Ther; 2018 Apr; 19(4):335-345. PubMed ID: 29333926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TTK is a favorable prognostic biomarker for triple-negative breast cancer survival.
    Xu Q; Xu Y; Pan B; Wu L; Ren X; Zhou Y; Mao F; Lin Y; Guan J; Shen S; Zhang X; Wang C; Zhong Y; Zhou L; Liang Z; Zhao H; Sun Q
    Oncotarget; 2016 Dec; 7(49):81815-81829. PubMed ID: 27833085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small breast epithelial mucin tumor tissue expression is associated with increased risk of recurrence and death in triple-negative breast cancer patients.
    Liu L; Liu Z; Qu S; Zheng Z; Liu Y; Xie X; Song F
    Diagn Pathol; 2013 May; 8():71. PubMed ID: 23635316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.